Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn,1 it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.